narrow therapeutic index drug

narrow therapeutic index drug

Clinical pharmacology Any pharmaceutical which has a < 2-fold difference between the minimum toxic concentration and minimum effective concentration in blood. See Therapeutic index.
Mentioned in ?
References in periodicals archive ?
Coumadin is a narrow therapeutic index drug that requires careful patient monitoring.
Why is it wrong for patients and their doctors to know when a narrow therapeutic index drug is switched?
Coumadin is a narrow therapeutic index drug, which means that there is a small difference between the amount needed to be effective in preventing strokes and related events and the amount which could cause internal bleeding and other complications," said Nick Teti, President of DuPont Merck's Pharmaceuticals Division.
DuPont Merck, the manufacturer of Coumadin(R) (warfarin sodium) crystalline, a widely used narrow therapeutic index drug, supports full disclosure in the prescribing and dispensing of NTI medications, said Howes.
Warfarin sodium is a Narrow Therapeutic Index drug with a narrow window between patient benefit and patient risk.
5) Narrow Therapeutic Index drugs are drugs that must be closely monitored by a physician because too much or too little medicine could produce serious adverse health conditions; this is true regardless of whether the product is brand or generic.
On a monthly basis, medication use and cost was measured and reported the number of medications and medication doses per nursing home resident per month; the number of laboratory measurements for narrow therapeutic index drugs per nursing home resident per month; and the cost of all oral medications per nursing home resident per month.
One pharmacist said substituting for narrow therapeutic index drugs often results in patients being re-evaluated by physicians, having additional lab tests run to monitor blood levels and receiving a new prescription for a different brand name drug not available in generic form.
NYSE: BRL) today hailed the decision by the Virginia Board of Pharmacy refusing to promulgate regulations restricting the substitution of generic Narrow Therapeutic Index drugs, including Warfarin Sodium.